Ashwini Gowryshankar1, Vinayak Nagaraja1, Guy D Eslick1. 1. The Whiteley-Martin Research Centre, The Discipline of Surgery, The University of Sydney, Sydney Medical School, Nepean, Penrith, New South Wales, Australia.
Abstract
BACKGROUND: The oncogenic potential of the Human Epidermal Growth Factor Receptor 2 (HER2) is well known in the context of breast cancer however; its relationship with the development of Barrett's Esophagus (BE) and Esophageal Cancer (EC) is unclear. The aim of this meta-analysis was to determine the overall prevalence and survival of HER2+ in BE & EC. PATIENTS AND METHODS: Several databases were searched including article reference lists. Inclusion criteria required that studies measured HER2 positivity in subjects with BE or EC. RESULTS: 33 studies were included in the meta-analysis (10 BE & 23 EC studies). The prevalence of HER2+ was found to be 24% (95% CI: 15-36%) in BE and 26% (95% CI: 19-34%) in EC. Squamous cell carcinoma (SCC) had a higher ER of 32% (95% CI: 20-48%) in comparison with adenocarcinoma (ADC) with an ER of 21% (95% CI: 14-32%). Sub group analyses showed a high geographical variance, Asia was found to be the highest prevalent area with an ER 42% (95% CI: 22-64%). The difference in survival rate between groups HER2- & HER2+ was found to be 7 months. CONCLUSIONS: Our results highlight a high prevalence of HER2+ in subjects with adenocarcinoma. HER2+ appears to decrease the survival time of EC patients.
BACKGROUND: The oncogenic potential of the Human Epidermal Growth Factor Receptor 2 (HER2) is well known in the context of breast cancer however; its relationship with the development of Barrett's Esophagus (BE) and Esophageal Cancer (EC) is unclear. The aim of this meta-analysis was to determine the overall prevalence and survival of HER2+ in BE & EC. PATIENTS AND METHODS: Several databases were searched including article reference lists. Inclusion criteria required that studies measured HER2 positivity in subjects with BE or EC. RESULTS: 33 studies were included in the meta-analysis (10 BE & 23 EC studies). The prevalence of HER2+ was found to be 24% (95% CI: 15-36%) in BE and 26% (95% CI: 19-34%) in EC. Squamous cell carcinoma (SCC) had a higher ER of 32% (95% CI: 20-48%) in comparison with adenocarcinoma (ADC) with an ER of 21% (95% CI: 14-32%). Sub group analyses showed a high geographical variance, Asia was found to be the highest prevalent area with an ER 42% (95% CI: 22-64%). The difference in survival rate between groups HER2- & HER2+ was found to be 7 months. CONCLUSIONS: Our results highlight a high prevalence of HER2+ in subjects with adenocarcinoma. HER2+ appears to decrease the survival time of EC patients.
Entities:
Keywords:
Barrett’s esophagus (BE); Human epidermal growth factor receptor 2 (HER2); esophageal cancer (EC); meta-analysis
Authors: S F Schoppmann; B Jesch; J Zacherl; F Wrba; M Hejna; J Maresch; F B Langer; M F Riegler; U Pluschnig; P Birner Journal: Br J Surg Date: 2011-05-25 Impact factor: 6.939
Authors: R Kim; M R Clarke; M F Melhem; M A Young; M M Vanbibber; A V Safatle-Ribeiro; U Ribeiro; J C Reynolds Journal: Dig Dis Sci Date: 1997-12 Impact factor: 3.199
Authors: Lasse Bremholm; Peter Funch-Jensen; Jan Eriksen; Lene Hendel; Troels Havelund; Peter Matzen Journal: Dan Med J Date: 2012-08 Impact factor: 1.240
Authors: Z He; Y Zhao; C Guo; Y Liu; M Sun; F Liu; X Wang; F Guo; K Chen; L Gao; T Ning; Y Pan; Y Li; S Zhang; C Lu; Z Wang; H Cai; Y Ke Journal: Br J Cancer Date: 2010-08-10 Impact factor: 7.640
Authors: M Q Chan; A E Blum; A K Chandar; A M L Kieber Emmons; Y Shindo; W Brock; G W Falk; M I Canto; J S Wang; P G Iyer; N J Shaheen; W M Grady; J A Abrams; P N Thota; K K Guda; A Chak Journal: Dis Esophagus Date: 2018-04-01 Impact factor: 3.429
Authors: L H McCormick Matthews; F Noble; J Tod; E Jaynes; S Harris; J N Primrose; C Ottensmeier; G J Thomas; T J Underwood Journal: Br J Cancer Date: 2015-06-25 Impact factor: 7.640
Authors: C-I Geppert; P Rümmele; M Sarbia; R Langer; M Feith; L Morrison; E Pestova; R Schneider-Stock; A Hartmann; T T Rau Journal: Br J Cancer Date: 2014-05-22 Impact factor: 7.640
Authors: F J C Ten Kate; S H van Olphen; M J Bruno; B P L Wijnhoven; J J B van Lanschot; L H J Looijenga; R C Fitzgerald; K Biermann Journal: Br J Surg Date: 2017-07-10 Impact factor: 6.939
Authors: R Stephen McCain; Damian T McManus; Stephen McQuaid; Jacqueline A James; Manuel Salto-Tellez; Nathan B Reid; Stephanie Craig; Chintapuza Chisambo; Victoria Bingham; Eamon McCarron; Eileen Parkes; Richard C Turkington; Helen G Coleman Journal: Cancer Causes Control Date: 2019-11-30 Impact factor: 2.506
Authors: Roelof J Beukinga; Da Wang; Arend Karrenbeld; Willemieke P M Dijksterhuis; Hette Faber; Johannes G M Burgerhof; Véronique E M Mul; Riemer H J A Slart; Robert P Coppes; John Th M Plukker Journal: Eur Radiol Date: 2020-11-05 Impact factor: 5.315